Indegene’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. They also approved an investment of up to €8.5 million in equity shares of Indegene Ireland Limited, a wholly-owned subsidiary. Additionally, the board approved the allotment of shares under ESOP and RSU plans and amendments to the Anti-Sexual Harassment Policy.
Financial Results Approved
The Board of Directors of Indegene has approved the unaudited standalone and consolidated financial results for Q2 FY26, which ended September 30, 2025. These results have been reviewed by the auditors, and include an unmodified opinion. The financial results are available on the company website.
Investment in Indegene Ireland
The board has approved an investment in equity shares of Indegene Ireland Limited, a wholly-owned subsidiary, up to an amount of Euro 8.5 million. This investment will be made in one or more tranches. The investment is intended to support the subsidiary’s capex requirements for business expansion.
Other Key Decisions
The board also approved the following:
- Allotment of shares under the ESOP 2020 Plan and RSU 2020 Plan.
- Amendment to the Anti-Sexual Harassment Policy.
- Noted grants under the RSU 2020 Plan, ESOP 2020 Plan and CSOP 2022 (CSOP Sub-Plan).
The board meeting commenced at 6:30 P.M. IST and concluded at 7:05 P.M. IST.
Financial Performance Highlights (Consolidated)
Key figures from the consolidated financial results for Q2 FY26:
- Revenue from operations: ₹8,042 million
- Total Income: ₹8,239 million
- Profit before tax: ₹1,331 million
- Profit for the period: ₹1,021 million
Financial Performance Highlights (Standalone)
Key figures from the standalone financial results for Q2 FY26:
- Revenue from operations: ₹3,067 million
- Total Income: ₹3,242 million
- Profit before tax: ₹775 million
- Profit for the period: ₹599 million
Source: BSE
